Published in Nat Rev Cancer on April 01, 2009
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Clonal evolution in cancer. Nature (2012) 11.07
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Defining the mode of tumour growth by clonal analysis. Nature (2012) 5.02
To differentiate or not--routes towards metastasis. Nat Rev Cancer (2012) 3.59
Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest (2010) 3.41
The perivascular niche regulates breast tumour dormancy. Nat Cell Biol (2013) 3.36
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer (2011) 2.77
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
Origins of metastatic traits. Cancer Cell (2013) 2.49
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer (2011) 2.16
Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. Genome Biol (2011) 2.11
Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer (2014) 2.09
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
Genetic and phenotypic diversity in breast tumor metastases. Cancer Res (2014) 1.96
Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol (2011) 1.92
Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell (2014) 1.88
Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends Cell Biol (2015) 1.87
Mechanisms governing metastatic dormancy and reactivation. Cell (2013) 1.81
Comparative genomic analysis of primary and synchronous metastatic colorectal cancers. PLoS One (2014) 1.80
Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin Cell Dev Biol (2009) 1.78
The evolving concept of cancer and metastasis stem cells. J Cell Biol (2012) 1.76
Cancer genomics: one cell at a time. Genome Biol (2014) 1.70
Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg (2010) 1.68
Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res (2011) 1.67
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One (2012) 1.63
The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res (2010) 1.54
Obligate progression precedes lung adenocarcinoma dissemination. Cancer Discov (2014) 1.47
Modeling metastasis in the mouse. Curr Opin Pharmacol (2010) 1.46
Selection and adaptation during metastatic cancer progression. Nature (2013) 1.46
ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res (2011) 1.44
The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) (2013) 1.40
Intravital microscopy: new insights into metastasis of tumors. J Cell Sci (2011) 1.36
Clinical relevance and biology of circulating tumor cells. Breast Cancer Res (2011) 1.34
SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J (2011) 1.33
Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev (2011) 1.32
Metastatic colonization by circulating tumour cells. Nature (2016) 1.31
N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med (2012) 1.24
A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet (2015) 1.23
TrAp: a tree approach for fingerprinting subclonal tumor composition. Nucleic Acids Res (2013) 1.23
Early dissemination seeds metastasis in breast cancer. Nature (2016) 1.20
Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol (2011) 1.18
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. Genome Res (2013) 1.15
Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer (2011) 1.15
What are the hallmarks of cancer? Nat Rev Cancer (2010) 1.14
Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol (2013) 1.14
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Nanoroughened surfaces for efficient capture of circulating tumor cells without using capture antibodies. ACS Nano (2012) 1.08
Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer (2012) 1.07
Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PLoS One (2012) 1.05
Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med (2012) 1.04
Cell adhesion and its endocytic regulation in cell migration during neural development and cancer metastasis. Int J Mol Sci (2012) 1.04
A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists. J Adv Res (2014) 1.03
Hypermutable DNA chronicles the evolution of human colon cancer. Proc Natl Acad Sci U S A (2014) 1.02
Biology and significance of circulating and disseminated tumour cells in colorectal cancer. Langenbecks Arch Surg (2012) 1.01
Regulation of tumor cell dormancy by tissue microenvironments and autophagy. Adv Exp Med Biol (2013) 1.00
Emerging role of nanomaterials in circulating tumor cell isolation and analysis. ACS Nano (2014) 1.00
Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines. Genes Chromosomes Cancer (2010) 0.98
Lost in migration. Nat Biotechnol (2010) 0.97
Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLoS Comput Biol (2015) 0.96
Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. Oncotarget (2015) 0.95
Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer (2013) 0.95
Breast cancer metastasis: issues for the personalization of its prevention and treatment. Am J Pathol (2013) 0.95
Emerging Biological Principles of Metastasis. Cell (2017) 0.94
Interplay of Stem Cell Characteristics, EMT, and Microtentacles in Circulating Breast Tumor Cells. Cancers (Basel) (2013) 0.94
Next-generation sequencing of disseminated tumor cells. Front Oncol (2013) 0.94
Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer. Nat Cell Biol (2015) 0.94
Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br J Cancer (2013) 0.94
Emerging roles of the tumor-associated stroma in promoting tumor metastasis. Cell Adh Migr (2012) 0.94
TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res (2014) 0.94
Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biol Ther (2015) 0.93
Conceptualizing a tool to optimize therapy based on dynamic heterogeneity. Phys Biol (2012) 0.93
Understanding tumor heterogeneity as functional compartments--superorganisms revisited. J Transl Med (2011) 0.93
Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Target (2012) 0.93
Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment. Cancer Res (2013) 0.93
Transposon-based screens for cancer gene discovery in mouse models. Semin Cancer Biol (2010) 0.93
The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications. Clin Exp Metastasis (2012) 0.93
Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. Cancer Res (2013) 0.93
Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing. BMC Cancer (2015) 0.92
ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma. Genes Cancer (2013) 0.91
Stromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors. Cancer Discov (2013) 0.91
The landscape of metastatic progression patterns across major human cancers. Oncotarget (2015) 0.91
Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients. Biomed Res Int (2014) 0.90
Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization. Cancer Microenviron (2014) 0.90
On the theory of tumor self-seeding: implications for metastasis progression in humans. Breast Cancer Res (2010) 0.90
The biology of circulating tumor cells. Oncogene (2015) 0.90
High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer. Genome Biol (2015) 0.89
Clonal expansion and linear genome evolution through breast cancer progression from pre-invasive stages to asynchronous metastasis. Oncotarget (2015) 0.89
The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis. Cancer Microenviron (2011) 0.89
Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. Nat Med (2015) 0.89
Reliable single cell array CGH for clinical samples. PLoS One (2014) 0.89
A robust method to analyze copy number alterations of less than 100 kb in single cells using oligonucleotide array CGH. PLoS One (2013) 0.88
Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer (2013) 0.88
Chromosomal copy number aberrations in colorectal metastases resemble their primary counterparts and differences are typically non-recurrent. PLoS One (2014) 0.88
Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells. Front Oncol (2012) 0.88
Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biol (2016) 0.88
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 18.08
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
Mutation selection and the natural history of cancer. Nature (1975) 9.73
Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer (2005) 9.04
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet (2008) 8.12
Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer (2008) 7.99
Systemic spread is an early step in breast cancer. Cancer Cell (2008) 7.91
Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med (2002) 7.66
Dissecting the metastatic cascade. Nat Rev Cancer (2004) 6.32
Selection of successive tumour lines for metastasis. Nat New Biol (1973) 5.03
From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A (2003) 4.79
Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med (1956) 4.76
I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. Ann Surg (1907) 4.69
Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol (2006) 4.47
Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A (2003) 4.47
Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell (2007) 4.30
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res (1997) 4.02
Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 3.95
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A (1999) 3.74
Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet (2002) 3.45
Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol (2009) 3.36
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell (2008) 3.01
Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol (1986) 2.93
Brain metastases: the HER2 paradigm. Clin Cancer Res (2007) 2.81
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer (2008) 2.72
The dormant cancer cell. Br Med J (1954) 2.69
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol (2005) 2.58
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol (2008) 2.57
Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol (2002) 2.48
The process of metastasisation for breast cancer. Eur J Cancer (2003) 2.30
Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer (2007) 2.27
Mechanisms of malignant progression. Carcinogenesis (2008) 2.25
On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol (1997) 2.23
Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst (1999) 2.21
Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst (1993) 2.14
Adaptation versus selection: the origins of metastatic behavior. Cancer Res (2007) 2.08
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs (2007) 2.08
Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell (2005) 2.03
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer (2008) 1.90
Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res (1984) 1.88
The genomic heritage of lymph node metastases: implications for clinical management of patients with breast cancer. Ann Surg Oncol (2008) 1.87
Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol (2008) 1.87
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
Age-dependent growth rate of primary breast cancer. Cancer (1993) 1.80
High resolution array-CGH analysis of single cells. Nucleic Acids Res (2006) 1.79
The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer (1999) 1.73
Metastatic patterns of renal carcinoma: an analysis of 687 necropsies. J Cancer Res Clin Oncol (1988) 1.70
The cross rates of growth of human mammary carcinoma. Cancer (1972) 1.69
RATES OF GROWTH OF PULMONARY METASTASES AND HOST SURVIVAL. Ann Surg (1964) 1.67
Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer (2002) 1.66
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol (1994) 1.64
Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer (2008) 1.63
Growth rate of hepatic metastases in colorectal carcinoma. Br J Surg (1988) 1.55
Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle (2006) 1.54
The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin (2008) 1.51
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer (1991) 1.47
The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin (2007) 1.46
Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun (2004) 1.45
Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell (2004) 1.41
Predicting the course of Gompertzian growth. Nature (1976) 1.39
Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A (1987) 1.36
An autopsy study of metastatic sites of breast cancer. Cancer Res (1973) 1.30
Haematogenous dissemination of cells from human renal adenocarcinomas. Br J Cancer (1988) 1.30
Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res (2004) 1.29
Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer (2002) 1.26
Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am J Pathol (1999) 1.25
Host genetics influence tumour metastasis. Nat Rev Cancer (2006) 1.25
Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A (2002) 1.15
The systemic progression of human cancer: a focus on the individual disseminated cancer cell--the unit of selection. Adv Cancer Res (2003) 1.14
Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma. Am J Surg Pathol (2007) 1.13
High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucleic Acids Res (2008) 1.12
Rates of growth of human neoplasms: Part II. J Surg Oncol (1996) 1.12
Carcinoma of the colon and rectum--growth rate. Ann Surg (1983) 1.07
Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res (1995) 1.07
Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathol Oncol Res (2007) 1.04
The many faces of tumor dormancy. APMIS (2008) 1.00
Foulds' dangerous idea revisited: the multistep development of tumors 40 years later. Adv Cancer Res (1998) 0.99
Do generalized metastases occur directly from the primary? J Chronic Dis (1975) 0.87
The direct molecular analysis of metastatic precursor cells in breast cancer: a chance for a better understanding of metastasis and for personalised medicine. Eur J Cancer (2008) 0.86
Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res (1999) 0.84
Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. J Surg Oncol (1991) 0.81